Ironwood Pharmaceuticals/$IRWD
1D1W1MYTD1Y5YMAX
Capital at risk
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
- Ticker
- $IRWD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- Boston, United States
- Website
- ironwoodpharma.com
IRWD Metrics
BasicAdvanced
$682M
5.23
$0.79
0.21
-
Price and volume
Market cap
$682M
Beta
0.21
52-week high
$5.78
52-week low
$1.26
Average daily volume
1.9M
Financial strength
Current ratio
6.063
Quick ratio
5.84
Long term debt to equity
-2.432
Total debt to equity
-2.452
Interest coverage (TTM)
7.23%
Profitability
EBITDA (TTM)
238.105
Gross margin (TTM)
77.22%
Net profit margin (TTM)
33.36%
Operating margin (TTM)
60.67%
Effective tax rate (TTM)
37.38%
Revenue per employee (TTM)
$3,890,000
Management effectiveness
Return on assets (TTM)
47.01%
Return on equity (TTM)
-55.26%
Valuation
Price to earnings (TTM)
5.234
Price to revenue (TTM)
1.731
Price to book
-4.22
Price to tangible book (TTM)
-4.17
Price to free cash flow (TTM)
3.631
Free cash flow yield (TTM)
27.54%
Free cash flow per share (TTM)
1.137
Growth
Revenue change (TTM)
26.19%
Earnings per share change (TTM)
-1,650.82%
3-year revenue growth (CAGR)
-3.05%
10-year revenue growth (CAGR)
6.20%
3-year earnings per share growth (CAGR)
-49.02%
10-year earnings per share growth (CAGR)
1.61%
What the Analysts think about IRWD
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
Analyst projections of the future price of Ironwood Pharmaceuticals stock.
Bulls say / Bears say
LINZESS is showing renewed commercial momentum: first-half US sales rose 44% year on year to $555 million, supported by improved net pricing and mid-single-digit prescription growth. Ironwood raised its 2026 US sales guidance to $1.15–$1.20 billion, implying growth of more than 30%. (Ironwood Pharmaceuticals)
The business is converting sales into cash and reducing financial risk: second-quarter adjusted EBITDA was $83 million, and Ironwood repaid its $200 million convertible notes using cash. Management expects gross debt below $300 million by year-end, which should leave more flexibility to fund development. (Ironwood Pharmaceuticals, The Motley Fool)
Apraglutide offers a potential second growth engine in a severe rare-GI condition. Its confirmatory STARS-2 Phase 3 trial is recruiting, and recent pooled programme data reported a consistent long-term safety profile while the once-weekly treatment showed positive efficacy signals. (Financial Times, Ironwood Pharmaceuticals)
Ironwood remains heavily dependent on LINZESS, so the franchise faces a material concentration risk. Recent analysis points to generic competition around the 2029 patent-expiry window, which could cause a sharp decline in the company’s main cash-generating product. (Seeking Alpha, Ironwood Pharmaceuticals 10-Q)
Apraglutide is not yet an approved product: the FDA has required a confirmatory Phase 3 trial despite positive earlier results. A failed or delayed STARS-2 read-out would remove the main planned replacement for LINZESS revenue after the patent cliff. (Ironwood Pharmaceuticals 10-Q, StockAnalysis)
The balance sheet still carries execution risk: at the end of June, Ironwood reported $79 million of cash and $385 million drawn on its revolving facility. The STARS-2 trial is also expected to lift R&D spending, so slower LINZESS cash generation or higher development costs could limit deleveraging. (StockTitan, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 26 Sept 2026.
IRWD Financial Performance
Revenues and expenses
IRWD Earnings Performance
Company profitability
Upcoming events
No upcoming events
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Business Wire4 weeks ago
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat2 months ago
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Business Wire2 months ago
Funds containing IRWD
AllUSDGBPEUR
Fund name | Fund size | $IRWD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.